Literature DB >> 6298372

Time course of improved neuromuscular function following plasma exchange alone and plasma exchange with prednisone/azathioprine in myasthenia gravis.

H S Milner-Brown, R G Miller.   

Abstract

Ten patients with myasthenia gravis (MG) were treated with weekly plasma exchange (PE) in combination with prednisone and azathioprine; 4 of the patients were treated with 3-6 PE alone, before instituting prednisone/azathioprine. Four clinico-physiological parameters of neuromuscular function as well as the anti-acetylcholine receptor antibody (anti-AChRAb) titers were measured 1-3 times per week. Evidence of improved neuromuscular function (NMF) was based on: (1) reduced % decrement of the maximum muscle compound potential following 2/s supramaximal nerve stimulation; (2) increased maximum force; (3) increased outstretched arm time, and (4) increased vital capacity. An early improvement in NMF occurred within the first 2 weeks (sometimes as early as 1-2 days), which was quantitatively comparable in patients treated with PE alone and PE plus prednisone/azathioprine. This early improvement reached a plateau, and was subsequently maintained for 3-4 weeks, followed by a later substantial improvement after 8-12 weeks of combined PE plus prednisone/azathioprine.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6298372     DOI: 10.1016/0022-510x(82)90041-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis.

Authors:  R Mantegazza; C Antozzi; D Peluchetti; A Sghirlanzoni; F Cornelio
Journal:  J Neurol       Date:  1988-11       Impact factor: 4.849

2.  A short plasma exchange protocol is effective in severe myasthenia gravis.

Authors:  C Antozzi; M Gemma; B Regi; E Berta; P Confalonieri; D Peluchetti; R Mantegazza; F Baggi; M Marconi; F Fiacchino
Journal:  J Neurol       Date:  1991-04       Impact factor: 4.849

3.  Myasthenia gravis treatment: twelve years experience on 110 patients.

Authors:  G Valli; S Jann; S Premoselli; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1987-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.